Skip to content
Cholangiocarcinoma Australia
  • Get Started
  • Give
  • Fundraise
  • How We Win
  • About Us
    • Contact us
    • Our Team
    • Our Board
  • Patient Portal
    • Articles
    • Order Patient Navigator Journal
    • Newly Diagnosed Patients
    • About CCA
      • Risk factors
      • Symptoms
      • Key Statistics
    • Meetings
    • Newsletter
    • Endorse A Professional
    • Staging and Grading
    • Biomarkers Matter
    • Treatment Options
    • Find a Specialist
    • Second Opinion
    • Find a Mentor
  • Trials
    • Clinical Trials
    • Clinical Trials Submission Portal
  • Clinicians Portal
  • Get Involved
    • Become A Mentor
    • Become a Volunteer
    • Become an Ambassador
    • Volunteer Positions Available0431 180 783
Latest News:
Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Brenda’s Testimonial
James Hastings Testimonial
Cholangiocarcinoma Foundation Australia Partners with Genomic Focus
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
Steven West: Cholangio Survivor
Cholangiocarcinoma Australia
  • Get Started
  • Give
  • Fundraise
  • How We Win
  • About Us
    • Contact us
    • Our Team
    • Our Board
  • Patient Portal
    • Articles
    • Order Patient Navigator Journal
    • Newly Diagnosed Patients
    • About CCA
      • Risk factors
      • Symptoms
      • Key Statistics
    • Meetings
    • Newsletter
    • Endorse A Professional
    • Staging and Grading
    • Biomarkers Matter
    • Treatment Options
    • Find a Specialist
    • Second Opinion
    • Find a Mentor
  • Trials
    • Clinical Trials
    • Clinical Trials Submission Portal
  • Clinicians Portal
  • Get Involved
    • Become A Mentor
    • Become a Volunteer
    • Become an Ambassador
    • Volunteer Positions Available0431 180 783
Latest:
Leading the Future of Cholangiocarcinoma Care—Because No One Else Will
Brenda’s Testimonial
James Hastings Testimonial
Cholangiocarcinoma Foundation Australia Partners with Genomic Focus
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
Steven West: Cholangio Survivor
Patients
Donate
Clinicians
MembersSteve2019-11-27T03:29:39+13:00

Connect With Us

Charity registration, ABN, tax status

Cholangiocarcinoma Foundation Australia is registered as a charity with the Australian Charities and Not-for-Profits Commission (ACNC). Cholangiocarcinoma Foundation Australia has Deductible Gift Recipient (DGR) status with the Australian Tax Office. Donations over $2 or more are tax-deductible. ABN: 93 665 038 102

“Built by survivors. Powered by action.” | © 2025

Copyright 2017 | All Rights Reserved | Cholangiocarcinoma Foundation Australia

Page load link
Go to Top